查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447730

多形性膠質母細胞瘤治療市場評估：按藥物、療法、最終用戶和地區劃分的機會和預測（2017-2031）

Glioblastoma Multiforme Treatment Market Assessment, By Drug, By Treatment, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5個工作天內

價格

2024年至2031年的預測期內，全球多形性膠質母細胞瘤治療市場規模預計將以8.78%的複合年增長率增長，從2023年的29.1億美元增長至57.1億美元。 近年來，市場經歷了顯著成長，預計未來將保持強勁成長速度。

全球多形性膠質母細胞瘤治療市場的成長是由於多形性膠質母細胞瘤在人群中患病率的不斷增加、創新療法的發展以及製藥和藥物發現行業的顯著增長所推動的。其驅動因素有以下幾個：包括： 政府措施、主要參與者增加投資開發優質高效的藥物、支持性監管框架以及醫療器材製造商和製藥公司之間的合資企業也有望進一步加速細胞腫瘤治療的成長市場。

多形性膠質母細胞瘤盛行率增加

由於全球多形性膠質母細胞瘤病例數量不斷增加，對多形性膠質母細胞瘤治療的需求顯著增加。 膠質母細胞瘤是一種快速轉移並引起進一步併發症的癌症，使其成為全球癌症患者死亡的主要原因之一。 根據德州大學西南醫學中心發表的一篇論文，全球每年診斷出超過 30 萬例膠質母細胞瘤。 據說它是成人中最常見的原發性惡性腦瘤。 膠質母細胞瘤患者的平均存活時間為 15-18 個月，這進一步凸顯了研發的必要性，以實現有效的治療過程，從而提高患者的存活率。

整合人工智慧加速藥物開發進程

人工智慧在製藥公司中的應用因其巨大的潛力而變得越來越重要，包括藥物開發過程中合成路線的分析和生成以及臨床試驗設計的優化。 多形性膠質母細胞瘤治療市場新興市場的領導者正在利用人工智慧和機器學習等最新先進技術來增強其研發流程，以在癌症治療過程中創造更有效率、更有益的治療方法。我們不斷致力於帶來治癒方法。

放射治療作為一種治療方法在市場上佔據主導地位

在多形性膠質母細胞瘤患者的各種治療方式中，放射治療的應用明顯增加。 放射治療在多形性膠質母細胞瘤的治療中發揮重要作用。 手術切除腫瘤後，建議單獨進行放射治療或與化療聯合治療，以殺死任何剩餘的癌細胞並防止未來的癌細胞生長。 多家公司參與開發創新療法，以提高放射治療的效率。 例如，2023年12月，Shuttle Pharmaceuticals Holdings, Inc.宣布已向FDA提交研究性新藥（IND）申請，以支持下一階段臨床試驗中羅□酮尿甘的開發。 Lopidoxuridine 是一種放射增敏劑，用於多形性膠質母細胞瘤的放射治療。 這種創新方法旨在提高癌症存活率並延長患者的生命。

本報告調查了全球多形性膠質母細胞瘤治療市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構和市場成長。它總結了影響因素分析、案例研究、競爭格局和主要公司概況。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球多形性膠質母細胞瘤治療市場展望

  • 市場規模/預測
  • 透過藥物
    • 替莫唑胺
    • 洛莫司汀
    • 貝伐珠單抗
    • 其他
  • 依治療方法
    • 手術
    • 放射治療
    • 化療
    • 標靶治療
    • 其他
  • 按最終用戶
    • 醫院
    • 門診手術中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球多形性膠質母細胞瘤治療市場展望：按地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 透過藥物
  • 依治療方法
  • 按最終用戶
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Azurity Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Co
  • Eli Lilly and Company
  • Lantern Pharma Inc.
  • Karyopharm Therapeutics Inc.

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11137

Global glioblastoma multiforme treatment market is projected to witness a CAGR of 8.78% during the forecast period 2024-2031, growing from USD 2.91 billion in 2023 to USD 5.71 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Growth in global glioblastoma multiforme treatment market is being driven by several factors such as increase in the prevalence of glioblastoma multiforme among the population, the development of innovative therapeutical drugs, and tremendous growth in the pharmaceutical and drug discovery industry. Government initiatives, growing investments by key market players to develop quality and efficient drugs, along with a supportive regulatory framework and collaborative ventures between medical device manufacturers and pharmaceutical companies will further promote the growth of the global glioblastoma multiforme treatment market.

The global glioblastoma multiforme treatment market is significantly undergoing robust growth due to the increasing prevalence of glioblastoma multiforme worldwide. As glioblastoma multiforme is a fast-growing tumor, it is highly essential to get treatment as early as possible to develop any fatal condition. Glioblastoma multiforme treatment methods such as surgery, chemotherapy, and radiation therapy play a crucial role in increasing the life expectancy of the patients. With the growing cases of glioblastoma, there is an increased demand for glioblastoma multiforme treatments due to which many leading players are continuously involved in launching innovative and efficient therapeutical drugs in their cancer treatment product portfolio, which is further propelling the growth of the global glioblastoma multiforme treatment market.

Government initiatives such as granting funds are being initiated to improve research and development in the market to improve medical facilities and provide efficient treatment to the patients. Product launches by key market players, along with increased collaboration activities such as mergers and acquisitions, partnership agreements, and new distribution agreements, drive the global glioblastoma multiforme treatment market. Moreover, several market leaders are undergoing extensive research and development in the market to launch innovative and efficient drugs. Celldex Therapeutics that develops targeted immunotherapy and biologics for the treatment of different types of cancers, announced that its latest drug "Varlilumab" is under clinical trial phase II and is most likely to progress into phase III.

Increasing Prevalence of Glioblastoma Multiforme

The demand for glioblastoma multiforme treatment is increasing significantly due to the rising number of glioblastoma multiforme cases worldwide. Glioblastoma is a leading cause of death among the cancer patients globally, as it is a type of cancer that spreads faster, leading to further health complications. According to an article published in "UT Southwestern Medical Center", globally, more than 300,000 cases of glioblastoma are diagnosed every year. It states that it is the most common primary malignant brain cancer in the adult population. The survival time for glioblastoma patients is only 15 to 18 months on an average, which further emphasizes the need for research and development to bring efficient treatment process that can increase the survival rate of the patients.

Integration of AI For Expediting Drug Development Process

The use of artificial intelligence in pharmaceutical companies is becoming more significant, due to its huge potential to analyze and generate synthesis pathways during the drug development process, as well as optimize clinical trial designs. Leading players in the glioblastoma multiforme treatment market are continuously involved in using the latest advanced technologies such as artificial intelligence and machine learning to enhance the research and development process, to bring more efficient therapeutic drugs, that can be beneficial in the treatment process of cancer.

For instance, in October 2023, Lantern Pharma Inc., using its AI-based platform, "RADR", announced that its latest innovative drug "LP-184" for the treatment of glioblastoma was published in the American Association for Cancer Research Journal. It states that LP-184 is a unique small molecule that has highly efficient CNS penetration and low nanomolar activity. With the help of its AI platform RADR, LP-184 is developed in such a way that it can repair damaged DNA. Moreover, it has been proven to be effective for patients with temozolomide resistance.

Radiation Therapy Dominates the Market in Terms of Treatment Methods

Among the different treatment methods for glioblastoma multiforme patients, the application of radiation therapy is increasing significantly. Radiation therapy plays a crucial part in the treatment of glioblastoma multiforme. After the surgical removal of a tumor, radiation therapy alone or in combination with chemotherapy is recommended to kill the remaining cancer cells and limit the growth of cancer cells in the future. Several companies are involved in developing innovative therapeutics to make radiation therapies more efficient. For instance, in December 2023 Shuttle Pharmaceuticals Holdings, Inc. announced application submission of an investigational new drug (IND) to the FDA, to support the company in the development of Ropidoxuridine in the next phase of the clinical trial. Ropidoxuridine is a radiation sensitizer, that is used in radiation therapy to treat glioblastoma multiforme. The innovative approach aims to increase cancer survival rates and prolong a patient's life.

Hospitals Hold a Major Share in Glioblastoma Multiforme Treatment Market

Among the end-user segment, hospitals account for the highest market share in the global glioblastoma multiforme treatment market. The increasing global population and rising number of hospitals are expected to cater to the demands and the dominance of the segment in the market. Glioblastoma multiform is an aggressive brain tumor that requires different treatments such as surgery, chemotherapy, and radiation therapy. Hospitals provide all these facilities, along with highly qualified surgeons and healthcare providers, which helps smoothen a patient's journey throughout the entire pathway from diagnosis to follow up and assessment. As the prevalence of cancer such as glioblastoma multiforme is increasing, the demand for hospitals in developed as well as developing countries are increasing, due to which countries are increasing the number of hospitals with advanced diagnostics and treatment facilities. For instance, according to the American Hospital Association, in the year 2023, there were 6,129 hospitals in the United States and more hospitals are under construction. Increased availability of a variety of treatment facilities in the healthcare setting, along with increased trust among the population regarding the reliability and quality of healthcare facilities provided in the hospitals is further driving the growth of hospital segment in the overall market.

North America Holds Significant Market Share

North America dominates global glioblastoma multiforme treatment market, due to its well-developed and highly efficient healthcare infrastructure and availability of the latest and advanced surgical techniques and therapeutical drugs for the treatment of glioblastoma multiforme. The growing prevalence of glioblastoma multiforme among the United States population is the prime factor, that is driving the growth of this market.

For instance, according to the "National Brain Tumor Society", in the United States, more than 10,000 individuals are affected by glioblastoma multiforme every year and it is estimated that out of all primary malignant brain tumors, 50.1% account for glioblastoma multiforme. The increasing prevalence requires efficient treatment such as surgeries, chemotherapy, and radiation therapy to increase the life span of the patients affected by this disease. Due to this, the demand for glioblastoma multiforme treatment is increasing in North America. Additionally, increased research and development in the market, along with the presence of key market players such as Amgen Inc and Merck & Co. further accelerate the demand for the global glioblastoma multiforme treatment market in the region.

Future Market Scenario (2024 - 2031F)

The global glioblastoma multiforme treatment market is expected to grow in the future, primarily due to increasing prevalence of glioblastoma multiforme worldwide. As the prevalence is increasing, pharmaceutical companies are constantly involved in extensive research and development of innovative therapeutical drugs for the treatment of the disease, along with mergers and acquisitions activities to enhance their product portfolio and expand their global market.

Additionally, the growth of the pharmaceutical industry, increased investments by organizations and government, frequent product launches, and increased FDA approvals by the regulatory bodies further lead to the growth of the global glioblastoma multiforme treatment market. For instance, in January 2024, Roche announced that its latest drug "Atezolizumab" is under clinical trial phase II and is most likely to get the FDA approval soon. The drug is expected to provide efficient treatment to the patients suffering from glioblastoma multiforme. These frequent product launches and favorable regulatory frameworks are further expected to escalate the growth of the market in the forecast period.

Key Players Landscape and Outlook

In the glioblastoma multiforme treatment market, pharmaceutical firms and biotechnological companies are consistently forming strategic partnerships and distribution agreements to enhance their productivity and global business. These collaboration activities play a crucial role in propelling the global glioblastoma multiforme treatment market's expansion. The strategic partnerships agreements, enable firms to gain in-depth insights into the market, strategically use each other's resources, markets, and technologies, and invest in research and development activities to bring innovative drug discovers and technological advancements in the treatment methods. Distribution agreements allow companies to expand their market presence globally. These collaborative initiatives promote innovation and expertise in product development, which improves patient health outcomes and contributes to the enduring and robust growth of the global glioblastoma multiforme treatment market.

For instance, in September 2023, Double Bond Pharmaceutical International AB, which is a pharmaceutical company that develops therapeutical drugs against cancer, announced its collaboration with Vivo Biopharma LLC, which is a subsidiary of Sauvie Inc. The collaboration will allow asset purchase and transition agreements for DBP's SI-053, which is a locally acting formulation of temozolomide, developed for the treatment of glioblastoma. As this latest drug has the potential to increase survival rate in patients suffering from glioblastoma, it is expected that the agreement will provide quality and advanced treatment to cancer patients and will support in elevating the market globally.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Glioblastoma Multiforme Treatment Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Drug
    • 4.2.1.Temozolomide
    • 4.2.2.Lomustine
    • 4.2.3.Bevacizumab
    • 4.2.4.Others
  • 4.3.By Treatment
    • 4.3.1.Surgery
    • 4.3.2.Radiation
    • 4.3.3.Chemotherapy
    • 4.3.4.Targeted Therapy
    • 4.3.5.Others
  • 4.4.By End-user
    • 4.4.1.Hospital
    • 4.4.2.Ambulatory Surgical Centers
    • 4.4.3.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Glioblastoma Multiforme Treatment Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Drug
      • 5.1.2.1.Temozolomide
      • 5.1.2.2.Lomustine
      • 5.1.2.3.Bevacizumab
      • 5.1.2.4.Others
    • 5.1.3.By Treatment
      • 5.1.3.1.Surgery
      • 5.1.3.2.Radiation
      • 5.1.3.3.Chemotherapy
      • 5.1.3.4.Targeted Therapy
      • 5.1.3.5.Others
    • 5.1.4.By End-user
      • 5.1.4.1.Hospital
      • 5.1.4.2.Ambulatory Surgical Centers
      • 5.1.4.3.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Drug
      • 5.1.5.2.1.Temozolomide
      • 5.1.5.2.2.Lomustine
      • 5.1.5.2.3.Bevacizumab
      • 5.1.5.2.4.Others
      • 5.1.5.3.By Treatment
      • 5.1.5.3.1.Surgery
      • 5.1.5.3.2.Radiation
      • 5.1.5.3.3.Chemotherapy
      • 5.1.5.3.4.Targeted Therapy
      • 5.1.5.3.5.Others
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospital
      • 5.1.5.4.2.Ambulatory Surgical Centers
      • 5.1.5.4.3.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Drug
  • 6.2.By Treatment
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.F. Hoffmann-La Roche Ltd
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Amgen Inc.
  • 13.3.Merck & Co., Inc.
  • 13.4.Pfizer Inc.
  • 13.5.Sun Pharmaceutical Industries Limited
  • 13.6.Azurity Pharmaceuticals, Inc.
  • 13.7.Bristol-Myers Squibb Co
  • 13.8.Eli Lilly and Company
  • 13.9.Lantern Pharma Inc.
  • 13.10.Karyopharm Therapeutics Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 4.Global Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 5.Global Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global Glioblastoma Multiforme Treatment Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 10.North America Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 11.North America Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 16.United States Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 17.United States Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 21.Canada Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 22.Canada Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 26.Mexico Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 27.Mexico Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 31.Europe Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 32.Europe Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 37.Germany Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 38.Germany Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 39.France Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 42.France Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 43.France Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 47.Italy Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 48.Italy Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 52.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 53.United Kingdom Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 57.Russia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 58.Russia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 62.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 63.Netherlands Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 67.Spain Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 68.Spain Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 72.Turkey Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 73.Turkey Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 77.Poland Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 78.Poland Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 82.South America Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 83.South America Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 88.Brazil Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 89.Brazil Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 93.Argentina Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 94.Argentina Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 98.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 99.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 101.India Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 104.India Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 105.India Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 106.China Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 109.China Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 110.China Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 114.Japan Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 115.Japan Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 119.Australia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 120.Australia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 124.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 125.Vietnam Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 129.South Korea Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 130.South Korea Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 134.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 135.Indonesia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 139.Philippines Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 140.Philippines Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 144.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 145.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa Glioblastoma Multiforme Treatment Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 150.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 151.Saudi Arabia Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 155.UAE Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 156.UAE Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa Glioblastoma Multiforme Treatment Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Glioblastoma Multiforme Treatment Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa Glioblastoma Multiforme Treatment Market Share (%), By Drug, 2017-2031F
  • Figure 160.South Africa Glioblastoma Multiforme Treatment Market Share (%), By Treatment, 2017-2031F
  • Figure 161.South Africa Glioblastoma Multiforme Treatment Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023